Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PXVX0047
- Development stage
- Unknown
- Lead developer
- Emergent BioSolutions
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PXVX0047 is a live-attenuated vaccine candidate designed to prevent Chikungunya virus (CHIKV) infection. Originally developed by PaxVax (which was subsequently acquired by Emergent BioSolutions), the vaccine utilizes a weakened version of the virus to elicit a robust immune response, including the production of neutralizing antibodies and the activation of T-cell mediated immunity. Chikungunya is a mosquito-borne viral disease characterized by acute fever and severe, often debilitating, joint pain. PXVX0047 has been evaluated in Phase 2 clinical trials to assess its safety and immunogenicity in healthy adults, where it demonstrated the ability to induce high titers of neutralizing antibodies.
- Other names
- Chikungunya vaccineLive-attenuated Chikungunya vaccine
Beyond the preview
Go deeper on PXVX0047.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PXVX0047.